TL;DR
This study validates the HEART score's utility in China for predicting major adverse cardiovascular events (MACEs) in low-risk acute chest pain patients. It demonstrates that the HEART score can effectively identify patients who can safely forgo further cardiac imaging, potentially reducing unnecessary testing by nearly 50%.
What Problem Does This Paper Address?
Acute chest pain is a frequent reason for emergency department visits, but only a fraction of these patients have acute coronary syndrome (ACS). Differentiating between low-risk and high-risk patients is crucial for appropriate management, avoiding both under-diagnosis of serious conditions and over-testing of benign cases. Current guidelines recommend risk stratification, but the application and validation of specific tools like the HEART score in diverse healthcare systems, such as China's, are essential. The paper addresses the need to confirm the HEART score's effectiveness in a Chinese population for both risk prediction and reducing the burden of unnecessary cardiac imaging.
Methods
The study employed a prospective observational design. Patients presenting to the emergency department with acute chest pain and a low initial risk score (TIMI risk score < 2) were enrolled. Baseline data, including demographics, medical history, and risk factors, were collected. The HEART score, a validated tool comprising history, electrocardiography, age, risk factors, and troponin I levels, was calculated for each participant. Patients were then followed for 30 days post-discharge to track major adverse cardiovascular events (MACEs), defined as acute myocardial infarction, cardiovascular mortality, or all-cause mortality. Statistical analysis included descriptive statistics, independent t-tests, Mann-Whitney U tests, chi-square tests, Fisher exact tests, and Cox proportional hazards regression to assess the predictive value of the HEART score.
Datasets
The study utilized data collected from 244 patients enrolled at the Third People's Hospital of Huizhou, China, between October 2016 and October 2017. This represents a newly collected dataset for the purpose of this study, focusing on a Chinese population.
Key Insights and Ideas
- Cross-cultural validation: The HEART score, developed and validated in Western countries, shows promise in a Chinese healthcare setting, suggesting its potential for broader global applicability.
- High sensitivity for safety: The finding of 100% sensitivity in predicting MACEs for the low-risk group is particularly impactful. It strongly suggests that patients identified as low-risk by the HEART score are highly unlikely to experience a significant cardiac event within the observed timeframe.
- Balancing risk and resource utilization: The study highlights the dual benefit of the HEART score: not only does it identify patients at risk, but it also provides a reliable mechanism to avoid unnecessary, costly, and potentially stressful cardiac imaging for a substantial portion of patients.
- Incremental risk increase: The Cox regression analysis revealing a 1.3-fold increased risk of MACEs for each one-category increase in the HEART score quantifies the score's graded predictive power.
Key Results
- A total of 244 patients were enrolled, with only 2 losses to follow-up.
- After 30 days, no patients in the low-risk HEART score group experienced MACEs.
- Two patients (1.5%) in the high-risk HEART score group experienced MACEs (both non-ST segment elevation acute myocardial infarction requiring percutaneous coronary intervention).
- The HEART score demonstrated 100% sensitivity and 46.7% specificity in predicting MACEs.
- The study estimated that the HEART score could reduce unnecessary cardiac testing by 46.3%.
- Cox proportional hazards regression showed that each one-category increase in the HEART score was associated with a 1.3-fold increased risk of MACEs (HR 1.32, 95% CI 1.08–1.62, P=.042).
Limitations and Future Work
The authors acknowledge several limitations:
- Short follow-up duration: The 30-day follow-up period might not capture all potential clinical events, especially for those with a delayed onset of symptoms.
- Single-center study: The findings may not be generalizable to other regions of China due to potential heterogeneity in healthcare systems.
- Pre-selected low-risk population: The study focused on patients with a TIMI risk score < 2. The applicability of the HEART score to patients with higher TIMI scores (≥ 2) requires further investigation.
- Comparison to 6-week standard: The HEART score is typically used to evaluate 6-week risk, and the 30-day follow-up might lead to under- or overestimation of its predictive value.
Future work should focus on longer-term follow-up studies, multi-center trials across diverse Chinese regions, and investigating the HEART score's utility in broader patient populations, including those with higher initial risk scores. Further research is also warranted to evaluate its effectiveness for long-term risk prediction in Chinese patients.
Summary updated